API Pharma

Recent studies found that T cells found in COVID-19 patients ‘bode well’ for long-term immunity.

T cells are a type of white blood cell that the immune system uses to help fight viruses.

Scientists found that in people who had recovered from COVID-19, the T cells react to SARS-CoV-2 virus, the cause of the disease.

This study reveals new information that will help researchers better understand immunity.

Read the full story: https://www.sciencemag.org/news/2020/05/t-cells-found-covid-19-patients-bode-well-long-term-immunity?fbclid=IwAR2JomL5K_XZ2K8eq9Z1FjIWZG2AsIWlINmq5o8nm6iaPpYDYMqfMvnErNc #

T cells found in COVID-19 patients ‘bode well’ for long-term immunity New findings suggest past infections may offer some protection against the novel coronavirus

Hear from our founder Dr. Vincent DeGennaro on the Pensacola Morning News on NewsRadio1620.

Dr. DeGennaro and Andrew McKay discuss the way API's Covid-rapid works and how it solves for some of the concerns about accuracy for antibody tests that look for the novel coronavirus.

Listen to the interview below and learn more on our website https://covid-rapid.com

Dr Vince DeGennero on Rapid COVID-19 Antibody Test Andrew McKay and Dr. DeGennero (Epidemiologist and Medical Director/CEO of Abacus Pharma International) discuss the new rapid COVID-19 antibody test from Sure Bio-Tech and distributed by API which fun